1463 / 1498
35
Highly criticized:
•
Poor protocol adherence
•
Non-inferiority goal in OS not met
•
Insufficient toxicity evaluation
•
Overall poor results, sub-optimal chemo
•
Neurotoxicity even with chemo alone (26%), with RT (49%)
•
Salvage improved survival, but carries high QOL/toxicity cost
No WBRT